Evicenter
MarkdownMedical informationP&T meetings
Lanifibranor (IVA337)

Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

Manufacturer
Inventiva
Last updated
220 sources

Product information and disease descriptionProduct descriptionProduct information

Product comparison

33 evidence topics · 30 sources

Approved and phase 3 competitors named by Inventiva in its annual report

“In March 2024, Madrigal received FDA approval of Rezdiffra for the treatment of patients with MASH with moderate to advanced liver fibrosis and received a conditional marketing authorization from the European Commission in August 2025.” (opens the source at this quote in a new tab)

“For example, Boehringer Ingelheim, Eli Lilly, Akero Therapeutics (a subsidiary of Novo Nordisk), GSK and Roche and 89bio are also evaluating their respective investigational MASH medications in Phase 3 clinical trials in patients with non-cirrhotic MASH and in patients with cirrhotic MASH.” (opens the source at this quote in a new tab)

“Other companies, including Sagimet, Boston Pharmaceuticals, Altimmune, AstraZeneca, Eli Lilly, NorthSea, Terns, Viking, BMS, Pfizer, and Regeneron and Gilead Sciences have drug candidates for the treatment of MASH that are in less advanced clinical or pre-clinical development stages.” (opens the source at this quote in a new tab)

“We may lose lanifibranor’s Fast Track Designation if the FDA concludes that Rezdiffra and/or Wegovy addresses the unmet medical need for patients with MASH.” (opens the source at this quote in a new tab)

“For example, lanifibranor has caused weight gain in certain patients and the potential for this side effect may, if approved, lead patients to prefer a GLP-1 agent for the treatment of MASH.” (opens the source at this quote in a new tab)

Resmetirom: month 12 histology in Trial 1 (NCT03900429), 888 F2 and F3 participants, missing biopsy counted as nonresponse
Endpoint at month 12Placebo (N=294)REZDIFFRA 80 mg (N=298)REZDIFFRA 100 mg (N=296)
Resolution of steatohepatitis and no worsening of liver fibrosis, Pathologist A (%)“13”“27”“36”
Difference vs. placebo (95% CI), Pathologist ANot applicable“14 (8, 20)”“23 (16, 30)”
Resolution of steatohepatitis and no worsening of liver fibrosis, Pathologist B (%)“9”“26”“24”
Difference vs. placebo (95% CI), Pathologist BNot applicable“17 (11, 23)”“15 (9, 21)”
Improvement in liver fibrosis and no worsening of steatohepatitis, Pathologist A (%)“15”“23”“28”
Difference vs. placebo (95% CI), Pathologist ANot applicable“8 (2, 14)”“13 (7, 20)”
Improvement in liver fibrosis and no worsening of steatohepatitis, Pathologist B (%)“13”“23”“24”
Difference vs. placebo (95% CI), Pathologist BNot applicable“11 (5, 17)”“11 (5, 17)”
Semaglutide: week 72 histology in Study 11 (NCT04822181), 800 F2 and F3 participants, reference-based multiple imputation
Endpoint at week 72Placebo (N=266)WEGOVY injection (N=534)Difference vs. placebo (95% CI)
Resolution of steatohepatitis and no worsening of liver fibrosis, response rate (%)“34”“63”“29 (21, 36)”
Improvement in liver fibrosis and no worsening of steatohepatitis, response rate (%)“22”“37”“14 (8, 21)”
Resolution of steatohepatitis and improvement in liver fibrosis, response rate (%)“16”“33”“17 (10, 23)”
Pegozafermin: acquisition of 89bio by Roche, agreement in September 2025 and tender offer completed in October 2025
Pegozafermin: ENLIVEN phase 2b week 24 histology, full analysis population with multiple imputation

“In this phase 2b, multicenter, double-blind, 24-week, randomized, placebo-controlled trial, we randomly assigned patients with biopsy-confirmed NASH and stage F2 or F3 (moderate or severe) fibrosis to receive subcutaneous pegozafermin at a dose of 15 mg or 30 mg weekly or 44 mg once every 2 weeks or placebo weekly or every 2 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Among the 222 patients who underwent randomization, 219 received pegozafermin or placebo. The percentage of patients who met the criteria for fibrosis improvement was 7% in the pooled placebo group, 22% in the 15-mg pegozafermin group (difference vs. placebo, 14 percentage points; 95% confidence interval [CI], −9 to 38), 26% in the 30-mg pegozafermin group (difference, 19 percentage points; 95% CI, 5 to 32; P = 0.009), and 27% in the 44-mg pegozafermin group (difference, 20 percentage points; 95% CI, 5 to 35; P = 0.008). The percentage of patients who met the criteria for NASH resolution was 2% in the placebo group, 37% in the 15-mg pegozafermin group (difference vs. placebo, 35 percentage points; 95% CI, 10 to 59), 23% in the 30-mg pegozafermin group (difference, 21 percentage points; 95% CI, 9 to 33), and 26% in the 44-mg pegozafermin group (difference, 24 percentage points; 95% CI, 10 to 37).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Missing end-point data (for 28 patients) were imputed with the use of multiple imputation by means of logistic regression with all collected outcomes. The full analysis population included all the enrolled patients who had undergone randomization and received at least one dose of pegozafermin or placebo and who had confirmed fibrosis stage F2 or F3 (indicating moderate or severe fibrosis) and a nonalcoholic fatty liver disease activity score of at least 4 at baseline, as assessed on independent review by a three-pathologist panel.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Survodutide: phase 2 week 48 histology in F1 to F3 MASH, 293 participants who received at least one dose
Tirzepatide: SYNERGY-NASH phase 2 week 52 histology in F2 or F3 MASH, 190 randomized with missing biopsies imputed

“We conducted a phase 2, dose-finding, multicenter, double-blind, randomized, placebo-controlled trial involving participants with biopsy-confirmed MASH and stage F2 or F3 (moderate or severe) fibrosis. Participants were randomly assigned to receive once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 52 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Among 190 participants who had undergone randomization, 157 had liver-biopsy results at week 52 that could be evaluated, with missing values imputed under the assumption that they would follow the pattern of results in the placebo group. The percentage of participants who met the criteria for resolution of MASH without worsening of fibrosis was 10% in the placebo group, 44% in the 5-mg tirzepatide group (difference vs. placebo, 34 percentage points; 95% confidence interval [CI], 17 to 50), 56% in the 10-mg tirzepatide group (difference, 46 percentage points; 95% CI, 29 to 62), and 62% in the 15-mg tirzepatide group (difference, 53 percentage points; 95% CI, 37 to 69) (P<0.001 for all three comparisons). The percentage of participants who had an improvement of at least one fibrosis stage without worsening of MASH was 30% in the placebo group, 55% in the 5-mg tirzepatide group (difference vs. placebo, 25 percentage points; 95% CI, 5 to 46), 51% in the 10-mg tirzepatide group (difference, 22 percentage points; 95% CI, 1 to 42), and 51% in the 15-mg tirzepatide group (difference, 21 percentage points; 95% CI, 1 to 42).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“(Funded by Eli Lilly; SYNERGY-NASH ClinicalTrials.gov number, NCT04166773.)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Pemvidutide: PERFORMA phase 3 trial in F2 to F3 MASH initiated in August 2026
FieldQuoted record
Sponsor“Altimmune, Inc.”
Status“Recruiting”
Study start (actual)“2026-07-30”
Primary completion (estimated)“2028-12”
Enrollment (estimated)“1800”
Arms“Pemvidutide 1.8 mg”
Arms“Pemvidutide 2.4 mg”
Pemvidutide: IMPACT phase 2b week 24 histology in F2 or F3 MASH, intention-to-treat population

“IMPACT is an ongoing 48-week international, randomised, double-blind, placebo-controlled, phase 2b trial in patients with biopsy-confirmed MASH and fibrosis stage F2 or F3.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The dual primary endpoints were MASH resolution without worsening of fibrosis or at least one stage liver fibrosis improvement without worsening of MASH at 24 weeks in the intention-to-treat population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“MASH resolution without fibrosis worsening was observed in 18 (20%) of 86 patients in the placebo group, 24 (58%) of 41 patients in the 1·2 mg pemvidutide group (difference of 38% [95% CI 21-56]; p<0·0001), and 45 (52%) of 85 patients in the 1·8 mg pemvidutide group (difference of 32% [95% CI 19-46]; p<0·0001). Fibrosis improvement without worsening of MASH was observed in 24 (28%) of 86 patients in the placebo group, 13 (33%) of 41 patients in the 1·2 mg pemvidutide group (difference of 5% [95% CI -13 to 22]; p=0·59), and 30 (36%) of 85 patients in the 1·8 mg pemvidutide group (difference of 8% [95% CI -6 to 22]; p=0·27).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Pemvidutide treatment met the primary endpoint of MASH resolution without worsening of fibrosis at 24 weeks but did not meet the other primary endpoint of fibrosis improvement without worsening of MASH at this timepoint.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Cross-trial comparison of adiponectin change: lanifibranor, resmetirom, efruxifermin, and pegozafermin, with the authors’ caveat that results may not be comparable
Product (trial, time point)DoseAbsolute change in adiponectin from baseline at end of treatment, µg/ml
Lanifibranor (NATIVE, 24 weeks)“800mg”“+ 11.95 (8.97 to14.94)”
Lanifibranor (NATIVE, 24 weeks)“1200mg”“+ 17.12 (14.29 to 19.96)”
Resmetirom (MAESTRO-NASH, 52 weeks)“80mg”“+ 0.86 (0.19)”
Resmetirom (MAESTRO-NASH, 52 weeks)“100mg”“+ 1.1 (0.19)”
Efruxifermin (HARMONY, 24 weeks)“28mg”“+ 1.4(0.74 to 2.08)”
Efruxifermin (HARMONY, 24 weeks)“50mg”“+ 3.0(2.34 to 3.71)”
Pegozafermin (ENLIVEN, 24 weeks)“15mg”“+ 1.1(0.7)”
Pegozafermin (ENLIVEN, 24 weeks)“30mg”“+ 1.1(0.3)”
Pegozafermin (ENLIVEN, 24 weeks)“44mg”“+ 1.2 (0.4)”
Network meta-analysis of 29 randomized trials including lanifibranor, with the authors’ stated limitations

“We searched PubMed and Embase databases from January 1, 2020 to December 1, 2024, for published randomized controlled trials comparing pharmacological interventions in patients with biopsy-proven MASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A total of 29 randomized controlled trials (n=9324) were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Data from eligible studies were extracted as intention-to-treat (ITT) analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Pegozafermin (RR: 3.46, CrI: 1.54–11.15), cilofexor + firsocostat (RR: 2.67, CrI: 1.05–8.13), denifanstat (RR: 1.94, CrI: 1.04–4.04), survodutide (RR: 1.86, CrI: 1.18– 3.28), obeticholic acid (RR: 1.85, CrI: 1.30–2.75), tirzepatide (RR: 1.77, CrI: 1.17–2.94), resmetirom (RR: 1.64, CrI: 1.27–2.20), and semaglutide (RR: 1.51, CrI: 1.23–1.90) were statistically better than placebo in achieving ≥1 stage of fibrosis improvement without worsening MASH (Figure 3A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Pegozafermin (RR: 8.65, CrI: 2.63–59.42), survodutide (RR: 6.62, CrI: 3.13–17.97), tirzepatide (RR: 4.65, CrI: 2.31–10.66), efruxifermin (RR: 3.51, CrI: 1.83–8.17), liraglutide (RR: 3.23, CrI: 1.11–14.17), vitamin E + pioglitazone (RR: 3.03, CrI: 1.31–9.04), resmetirom (RR: 2.54, CrI: 1.86–3.55), pioglitazone (RR: 2.29, CrI: 1.41–4.03), denifanstat (RR: 2.03, CrI: 1.04–4.72), semaglutide (RR: 1.87, CrI: 1.60–2.24), and lanifibranor (RR: 1.93, CrI: 1.30–3.02) were statistically better than placebo in achieving MASH resolution without worsening fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“First, we acknowledge the modest number of trials with direct comparisons between pharmacological therapies, and the small number of trials for each agent; hence, most comparisons between treatments were based on indirect evidence; head-to-head trials versus other drugs should be considered to validate our findings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Comparability between trials was further limited by their heterogeneity in design and population (eg, demographics and comorbidities).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote